Gartner Inc. IT will release first-quarter 2026 results on May 5, before market open.
IT has an impressive earnings surprise history. In the four trailing quarters, it surpassed the Zacks Consensus Estimate, with an average surprise of 10.3%.
Gartner, Inc. Price and EPS Surprise
Gartner, Inc. price-eps-surprise | Gartner, Inc. Quote
Gartner’s Q1 Expectations
The Zacks Consensus Estimate for the top line is pinned at $1.5 billion, implying a marginal dip from the year-ago quarter’s actual.
The consensus estimate for the Insights segment’s revenues is set at $1.3 billion, suggesting a 2.9% year-over-year dip. The consensus estimate for Conferences’ revenues is kept at $75 million, hinting at a 2.7% rise from that reported in the same quarter last year. For Consulting, the Zacks Consensus Estimate for revenues is set at $139 million, suggesting a marginal dip from the prior-year quarter’s actual.
For gross contribution, the consensus estimate for Insights is kept at $1 billion, indicating 1.9% growth from the year-ago quarter’s actual. For conferences, the Zacks Consensus Estimate is pegged at $29 million, suggesting a 7.4% year-over-year increase. The consensus mark for consulting is at $51 million, implying a 3.8% decline from the year-ago quarter’s actual.
The consensus estimate for earnings per share is $2.99, suggesting slight growth from the year-ago quarter.
What Our Model Says About IT
Our proven model does not conclusively predict an earnings beat for Gartner this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IT has an Earnings ESP of 0.00% and a Zacks Rank of 4 (Sell) at present.
Stocks to Consider
Here are a few stocks, according to our model, that have the right combination of elements to beat on earnings this season.
Coherent Corp. COHR: The Zacks Consensus Estimate for third-quarter 2026 revenues is pegged at $1.8 billion, hinting at an 18.8% jump from the year-ago quarter’s actual. For earnings, the consensus mark is pegged at $1.41 per share, a 55% year-over-year rally from the year-ago quarter. COHR missed the consensus estimate in the trailing four quarters, with an average surprise of 7.7%.
COHR has an Earnings ESP of +3.08% and a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
It is scheduled to declare first-quarter 2026 results on May 6.
BridgeBio Pharma BBIO: The Zacks Consensus Estimate for the company’s first-quarter 2026 revenues is pinned at $179.8 million, suggesting growth of 54.2% from the year-ago quarter’s actual. For loss, the consensus mark is set at 70 cents per share compared with a loss of 88 cents in the year-ago quarter. BBIO beat the consensus estimate for earnings in one of the four quarters and missed thrice, with an average negative surprise of 10.9%.
BBIO has an Earnings ESP of +1.28% and a Zacks Rank of 3 at present. The company is scheduled to declare first-quarter 2026 results on May 7.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpGartner, Inc. (IT) : Free Stock Analysis Report
Coherent Corp. (COHR) : Free Stock Analysis Report
BridgeBio Pharma, Inc. (BBIO) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
